Annual Net Income
$249.70 M
+$95.20 M+61.62%
31 December 2023
Summary:
Neurocrine Biosciences annual net profit is currently $249.70 million, with the most recent change of +$95.20 million (+61.62%) on 31 December 2023. During the last 3 years, it has fallen by -$157.60 million (-38.69%). NBIX annual net income is now -38.69% below its all-time high of $407.30 million, reached on 31 December 2020.NBIX Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
$129.80 M
+$64.80 M+99.69%
30 September 2024
Summary:
Neurocrine Biosciences quarterly net profit is currently $129.80 million, with the most recent change of +$64.80 million (+99.69%) on 30 September 2024. Over the past year, it has increased by +$46.70 million (+56.20%). NBIX quarterly net income is now -62.69% below its all-time high of $347.90 million, reached on 31 December 2020.NBIX Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
$385.90 M
+$46.70 M+13.77%
30 September 2024
Summary:
Neurocrine Biosciences TTM net profit is currently $385.90 million, with the most recent change of +$46.70 million (+13.77%) on 30 September 2024. Over the past year, it has increased by +$194.90 million (+102.04%). NBIX TTM net income is now -13.24% below its all-time high of $444.80 million, reached on 30 September 2021.NBIX TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBIX Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +61.6% | +56.2% | +102.0% |
| 3 y3 years | -38.7% | +476.9% | -13.2% |
| 5 y5 years | +1083.4% | +141.3% | +1731.8% |
NBIX Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -38.7% | +178.7% | -12.1% | +269.4% | -13.2% | +3063.1% |
| 5 y | 5 years | -38.7% | +1083.4% | -62.7% | +269.4% | -13.2% | +3063.1% |
| alltime | all time | -38.7% | +220.4% | -62.7% | +201.4% | -13.2% | +275.5% |
Neurocrine Biosciences Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $129.80 M(+99.7%) | $385.90 M(+13.8%) |
| June 2024 | - | $65.00 M(+49.8%) | $339.20 M(-8.2%) |
| Mar 2024 | - | $43.40 M(-70.6%) | $369.70 M(+48.1%) |
| Dec 2023 | $249.70 M(+61.6%) | $147.70 M(+77.7%) | $249.70 M(+30.7%) |
| Sept 2023 | - | $83.10 M(-13.0%) | $191.00 M(+8.3%) |
| June 2023 | - | $95.50 M(-224.7%) | $176.40 M(+175.6%) |
| Mar 2023 | - | -$76.60 M(-186.1%) | $64.00 M(-58.6%) |
| Dec 2022 | $154.50 M(+72.4%) | $89.00 M(+29.9%) | $154.50 M(+165.5%) |
| Sept 2022 | - | $68.50 M(-505.3%) | $58.20 M(+377.0%) |
| June 2022 | - | -$16.90 M(-221.6%) | $12.20 M(-82.9%) |
| Mar 2022 | - | $13.90 M(-290.4%) | $71.40 M(-20.3%) |
| Dec 2021 | $89.60 M(-78.0%) | -$7.30 M(-132.4%) | $89.60 M(-79.9%) |
| Sept 2021 | - | $22.50 M(-46.8%) | $444.80 M(+22.0%) |
| June 2021 | - | $42.30 M(+31.8%) | $364.70 M(-9.3%) |
| Mar 2021 | - | $32.10 M(-90.8%) | $402.00 M(-1.3%) |
| Dec 2020 | $407.30 M(+1000.8%) | $347.90 M(-704.0%) | $407.30 M(+336.1%) |
| Sept 2020 | - | -$57.60 M(-172.4%) | $93.40 M(-54.4%) |
| June 2020 | - | $79.60 M(+112.8%) | $204.80 M(+16.0%) |
| Mar 2020 | - | $37.40 M(+10.0%) | $176.50 M(+377.0%) |
| Dec 2019 | $37.00 M(+75.4%) | $34.00 M(-36.8%) | $37.00 M(+75.6%) |
| Sept 2019 | - | $53.80 M(+4.9%) | $21.07 M(+16.8%) |
| June 2019 | - | $51.30 M(-150.2%) | $18.03 M(-146.0%) |
| Mar 2019 | - | -$102.10 M(-665.1%) | -$39.18 M(-285.7%) |
| Dec 2018 | $21.10 M(-114.8%) | $18.07 M(-64.4%) | $21.10 M(+112.6%) |
| Sept 2018 | - | $50.76 M(-958.5%) | $9.93 M(-119.1%) |
| June 2018 | - | -$5.91 M(-85.9%) | -$51.96 M(-51.0%) |
| Mar 2018 | - | -$41.82 M(-706.6%) | -$106.03 M(-25.6%) |
| Dec 2017 | -$142.54 M(+1.0%) | $6.89 M(-162.0%) | -$142.54 M(-26.6%) |
| Sept 2017 | - | -$11.13 M(-81.5%) | -$194.09 M(-11.7%) |
| June 2017 | - | -$59.98 M(-23.4%) | -$219.86 M(+9.8%) |
| Mar 2017 | - | -$78.33 M(+75.4%) | -$200.15 M(+41.9%) |
| Dec 2016 | -$141.09 M(+58.7%) | -$44.66 M(+21.1%) | -$141.09 M(+12.2%) |
| Sept 2016 | - | -$36.89 M(-8.4%) | -$125.75 M(+2.0%) |
| June 2016 | - | -$40.28 M(+109.1%) | -$123.29 M(+15.2%) |
| Mar 2016 | - | -$19.26 M(-34.3%) | -$107.00 M(+20.3%) |
| Dec 2015 | -$88.93 M(+46.9%) | -$29.32 M(-14.9%) | -$88.93 M(+12.5%) |
| Sept 2015 | - | -$34.44 M(+43.6%) | -$79.06 M(+30.7%) |
| June 2015 | - | -$23.99 M(+1912.3%) | -$60.50 M(+21.3%) |
| Mar 2015 | - | -$1.19 M(-93.9%) | -$49.89 M(-17.6%) |
| Dec 2014 | -$60.54 M(+31.4%) | -$19.44 M(+22.5%) | -$60.54 M(+17.0%) |
| Sept 2014 | - | -$15.88 M(+18.6%) | -$51.74 M(+10.1%) |
| June 2014 | - | -$13.38 M(+13.0%) | -$47.00 M(+2.5%) |
| Mar 2014 | - | -$11.84 M(+11.3%) | -$45.86 M(-0.5%) |
| Dec 2013 | -$46.09 M(-1017.2%) | -$10.64 M(-4.4%) | -$46.09 M(+77.6%) |
| Sept 2013 | - | -$11.13 M(-9.1%) | -$25.96 M(+45.0%) |
| June 2013 | - | -$12.24 M(+1.4%) | -$17.91 M(+190.5%) |
| Mar 2013 | - | -$12.07 M(-227.2%) | -$6.16 M(-222.7%) |
| Dec 2012 | $5.03 M(-86.6%) | $9.49 M(-408.3%) | $5.03 M(-260.3%) |
| Sept 2012 | - | -$3.08 M(+514.4%) | -$3.13 M(-110.0%) |
| June 2012 | - | -$501.00 K(-43.5%) | $31.33 M(-7.3%) |
| Mar 2012 | - | -$886.00 K(-166.6%) | $33.80 M(-10.0%) |
| Dec 2011 | $37.57 M(-571.5%) | $1.33 M(-95.8%) | $37.57 M(-3.0%) |
| Sept 2011 | - | $31.38 M(+1488.2%) | $38.73 M(+262.7%) |
| June 2011 | - | $1.98 M(-31.4%) | $10.68 M(-22.9%) |
| Mar 2011 | - | $2.88 M(+15.9%) | $13.85 M(+493.1%) |
| Dec 2010 | -$7.97 M | $2.49 M(-25.4%) | $2.34 M(-129.0%) |
| Sept 2010 | - | $3.33 M(-35.3%) | -$8.07 M(-58.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2010 | - | $5.15 M(-159.7%) | -$19.58 M(-51.1%) |
| Mar 2010 | - | -$8.64 M(+9.1%) | -$40.01 M(-21.6%) |
| Dec 2009 | -$51.04 M(-42.4%) | -$7.92 M(-3.2%) | -$51.04 M(-29.1%) |
| Sept 2009 | - | -$8.18 M(-46.5%) | -$71.98 M(-11.7%) |
| June 2009 | - | -$15.28 M(-22.3%) | -$81.51 M(-6.5%) |
| Mar 2009 | - | -$19.66 M(-31.8%) | -$87.20 M(-1.6%) |
| Dec 2008 | -$88.61 M(-57.3%) | -$28.85 M(+62.9%) | -$88.61 M(-52.8%) |
| Sept 2008 | - | -$17.71 M(-15.5%) | -$187.73 M(-4.8%) |
| June 2008 | - | -$20.97 M(-0.5%) | -$197.26 M(-2.7%) |
| Mar 2008 | - | -$21.08 M(-83.5%) | -$202.66 M(-2.2%) |
| Dec 2007 | -$207.30 M(+93.4%) | -$127.97 M(+369.8%) | -$207.30 M(+120.4%) |
| Sept 2007 | - | -$27.24 M(+3.3%) | -$94.04 M(-11.2%) |
| June 2007 | - | -$26.36 M(+2.5%) | -$105.94 M(-1.0%) |
| Mar 2007 | - | -$25.72 M(+74.8%) | -$107.02 M(-0.2%) |
| Dec 2006 | -$107.20 M(+383.1%) | -$14.71 M(-62.4%) | -$107.20 M(-7.9%) |
| Sept 2006 | - | -$39.14 M(+42.6%) | -$116.40 M(+127.8%) |
| June 2006 | - | -$27.45 M(+6.0%) | -$51.11 M(+74.7%) |
| Mar 2006 | - | -$25.90 M(+8.3%) | -$29.26 M(+31.9%) |
| Dec 2005 | -$22.19 M(-51.5%) | -$23.91 M(-191.4%) | -$22.19 M(+17.4%) |
| Sept 2005 | - | $26.15 M(-566.6%) | -$18.90 M(-59.5%) |
| June 2005 | - | -$5.60 M(-70.2%) | -$46.70 M(-10.6%) |
| Mar 2005 | - | -$18.83 M(-8.7%) | -$52.22 M(+14.1%) |
| Dec 2004 | -$45.77 M(+51.3%) | -$20.61 M(+1151.7%) | -$45.77 M(+108.4%) |
| Sept 2004 | - | -$1.65 M(-85.2%) | -$21.96 M(-27.2%) |
| June 2004 | - | -$11.13 M(-10.1%) | -$30.15 M(+3.1%) |
| Mar 2004 | - | -$12.38 M(-487.7%) | -$29.25 M(-3.3%) |
| Dec 2003 | -$30.26 M(-68.0%) | $3.19 M(-132.5%) | -$30.26 M(-58.1%) |
| Sept 2003 | - | -$9.83 M(-3.8%) | -$72.24 M(-12.6%) |
| June 2003 | - | -$10.22 M(-23.6%) | -$82.64 M(-10.3%) |
| Mar 2003 | - | -$13.39 M(-65.5%) | -$92.16 M(-2.5%) |
| Dec 2002 | -$94.54 M(+156.1%) | -$38.79 M(+91.7%) | -$94.54 M(+34.4%) |
| Sept 2002 | - | -$20.23 M(+2.4%) | -$70.36 M(+47.8%) |
| June 2002 | - | -$19.75 M(+25.3%) | -$47.62 M(+15.5%) |
| Mar 2002 | - | -$15.76 M(+7.9%) | -$41.21 M(+11.7%) |
| Dec 2001 | -$36.91 M(+28.1%) | -$14.61 M(-682.8%) | -$36.91 M(+16.3%) |
| Sept 2001 | - | $2.51 M(-118.8%) | -$31.73 M(-25.1%) |
| June 2001 | - | -$13.34 M(+16.4%) | -$42.38 M(+23.8%) |
| Mar 2001 | - | -$11.46 M(+21.5%) | -$34.22 M(+18.8%) |
| Dec 2000 | -$28.81 M(+71.5%) | -$9.43 M(+16.0%) | -$28.81 M(+24.9%) |
| Sept 2000 | - | -$8.13 M(+56.7%) | -$23.07 M(+19.3%) |
| June 2000 | - | -$5.19 M(-14.1%) | -$19.34 M(+3.2%) |
| Mar 2000 | - | -$6.05 M(+63.4%) | -$18.75 M(+11.6%) |
| Dec 1999 | -$16.80 M(-16.0%) | -$3.70 M(-15.9%) | -$16.80 M(-15.6%) |
| Sept 1999 | - | -$4.40 M(-4.3%) | -$19.90 M(+2.1%) |
| June 1999 | - | -$4.60 M(+12.2%) | -$19.50 M(-14.8%) |
| Mar 1999 | - | -$4.10 M(-39.7%) | -$22.90 M(+14.5%) |
| Dec 1998 | -$20.00 M(-492.2%) | -$6.80 M(+70.0%) | -$20.00 M(+51.5%) |
| Sept 1998 | - | -$4.00 M(-50.0%) | -$13.20 M(+57.1%) |
| June 1998 | - | -$8.00 M(+566.7%) | -$8.40 M(+2700.0%) |
| Mar 1998 | - | -$1.20 M(<-9900.0%) | -$300.00 K(-106.0%) |
| Dec 1997 | $5.10 M(-13.6%) | $0.00(-100.0%) | $5.00 M(-47.4%) |
| Sept 1997 | - | $800.00 K(+700.0%) | $9.50 M(+14.5%) |
| June 1997 | - | $100.00 K(-97.6%) | $8.30 M(-17.0%) |
| Mar 1997 | - | $4.10 M(-8.9%) | $10.00 M(+69.5%) |
| Dec 1996 | $5.90 M | $4.50 M(-1225.0%) | $5.90 M(+321.4%) |
| Sept 1996 | - | -$400.00 K(-122.2%) | $1.40 M(-22.2%) |
| June 1996 | - | $1.80 M | $1.80 M |
FAQ
- What is Neurocrine Biosciences annual net profit?
- What is the all time high annual net income for Neurocrine Biosciences?
- What is Neurocrine Biosciences annual net income year-on-year change?
- What is Neurocrine Biosciences quarterly net profit?
- What is the all time high quarterly net income for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly net income year-on-year change?
- What is Neurocrine Biosciences TTM net profit?
- What is the all time high TTM net income for Neurocrine Biosciences?
- What is Neurocrine Biosciences TTM net income year-on-year change?
What is Neurocrine Biosciences annual net profit?
The current annual net income of NBIX is $249.70 M
What is the all time high annual net income for Neurocrine Biosciences?
Neurocrine Biosciences all-time high annual net profit is $407.30 M
What is Neurocrine Biosciences annual net income year-on-year change?
Over the past year, NBIX annual net profit has changed by +$95.20 M (+61.62%)
What is Neurocrine Biosciences quarterly net profit?
The current quarterly net income of NBIX is $129.80 M
What is the all time high quarterly net income for Neurocrine Biosciences?
Neurocrine Biosciences all-time high quarterly net profit is $347.90 M
What is Neurocrine Biosciences quarterly net income year-on-year change?
Over the past year, NBIX quarterly net profit has changed by +$46.70 M (+56.20%)
What is Neurocrine Biosciences TTM net profit?
The current TTM net income of NBIX is $385.90 M
What is the all time high TTM net income for Neurocrine Biosciences?
Neurocrine Biosciences all-time high TTM net profit is $444.80 M
What is Neurocrine Biosciences TTM net income year-on-year change?
Over the past year, NBIX TTM net profit has changed by +$194.90 M (+102.04%)